What Researchers Did
Researchers reported a case of refractory vasculitic ulcers in a systemic lupus erythematosus (SLE) patient treated with rituximab and hyperbaric oxygen therapy after other treatments failed.
What They Found
The patient experienced sustained clinical improvement and a reduction in prednisolone dose after receiving rituximab, which was well-tolerated. Concomitant methotrexate and hyperbaric oxygen therapy may have also contributed to the recovery of the vasculitic ulcers.
What This Means for Canadian Patients
This case report suggests that rituximab, possibly combined with hyperbaric oxygen therapy, could be a treatment option for Canadian patients with refractory SLE-related vasculitic ulcers when standard therapies are ineffective. However, as a single case, further research is needed to confirm its broader applicability and efficacy.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
The main limitation of this study is that it is a single case report, which limits the generalizability of its findings.